You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

89Zr-TLX250 PET/CT

Showing 1 - 25 of 9,174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 14, 2023

Triple Negative Breast Cancer Trial in Saint-Herblain (89Zr-TLX250 PET/CT)

Recruiting
  • Triple Negative Breast Cancer
  • 89Zr-TLX250 PET/CT
  • Saint-Herblain, France
    ICO René Gauducheau
Oct 18, 2021

Bladder Cancer Trial in Saint Herblain (89Zr-TLX250 PET/CT)

Recruiting
  • Bladder Cancer
  • 89Zr-TLX250 PET/CT
  • Saint Herblain, France
    Institut de cancerologie de l'Ouest
Nov 24, 2021

Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma Trial in Yokohama City (89Zr-girentuximab)

Completed
  • Carcinoma, Renal Cell
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-girentuximab
  • Yokohama City, Kanagawa, Japan
    Yokohama City University Hospital
Aug 18, 2021

Solid Tumor, Adult, Advanced Solid Tumor, Advanced Renal Cell Carcinoma Trial in Australia (89Zr-TLX250, 177Lu-TLX250 and

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • 89Zr-TLX250
  • 177Lu-TLX250 and Peposertib
  • North Ryde, New South Wales, Australia
  • +4 more
May 22, 2023

Clear Cell Renal Cell Carcinoma Trial in Worldwide (89Zr-girentuximab)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-girentuximab
  • Duarte, California
  • +29 more
Aug 4, 2021

Multiple Myeloma, Plasma Cell Myeloma Trial in San Francisco (drug, procedure, other)

Not yet recruiting
  • Multiple Myeloma
  • Plasma Cell Myeloma
  • Zirconium Zr 89-DFO-YS5
  • +3 more
  • San Francisco, California
    University of California, San Francisco
May 26, 2023

Urothelial Carcinoma Trial in Murdoch (89Zr-Girentuximab)

Recruiting
  • Urothelial Carcinoma
  • Murdoch, Western Australia, Australia
    Fiona Stanley Hospital
Sep 8, 2021

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Recruiting
  • Neurofibromatosis 2
  • Bevacizumab Zirconium Zr-89
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Jan 5, 2023

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Panitumumab
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 16, 2023

Multiple Myeloma Trial (89Zr-DFO-daratumumab, PET/CT)

Withdrawn
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2022

Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

Recruiting
  • Large B-cell Lymphoma
  • DLBCL
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 3, 2022

Melanoma (Skin) Trial in Philadelphia (89Zr-Df-IAB22M2C PET/CT)

Enrolling by invitation
  • Melanoma (Skin)
  • 89Zr-Df-IAB22M2C PET/CT
  • Philadelphia, Pennsylvania
    Perleman Center for Advanced Medicine
May 31, 2022

CD8+ T-cell PET/CT Imaging in COVID-19 Patients

Recruiting
  • Lymphopenia Due to COVID-19
  • +2 more
  • [89Zr]Df-IAB22M2C PET/CT scan
  • Nijmegen, Gelderland, Netherlands
    Radboud university medical center
Jun 2, 2022

Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma Trial in Australia, Netherlands, United States

Recruiting
  • Melanoma
  • +3 more
  • 89Zr-Df-Crefmirlimab
  • Little Rock, Arkansas
  • +7 more
Jul 11, 2022

Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in San Francisco (drug, biological, procedure)

Recruiting
  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
    University of California, San Francisco
Mar 29, 2022

HER2-positive Solid Tumor, HER-2 Positive Cancer Trial (89Zr-trastuzumab)

Withdrawn
  • HER2-positive Solid Tumor
  • HER-2 Positive Cancer
  • (no location specified)
Dec 7, 2021

Head-and-neck Squamous Cell Carcinoma Trial in San Francisco (89Zr-panitumumab IV, Panitumumab)

Not yet recruiting
  • Head-and-neck Squamous Cell Carcinoma
  • San Francisco, California
    Stanford Cancer Institute
Jun 14, 2022

Multiple Myeloma Trial in Irvine (89Zr-daratumumab PET/CT)

Recruiting
  • Multiple Myeloma
  • 89Zr-daratumumab PET/CT
  • Irvine, California
    Hoag Memorial Hospital Presbyterian
Aug 1, 2022

Positron-Emission Tomography, Metastatic Solid Tumors Trial in United States (8?Zr-Df-IAB22M2C)

Completed
  • Positron-Emission Tomography
  • Metastatic Solid Tumors
  • Birmingham, Alabama
  • +14 more
Nov 15, 2022

Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

Available
  • Clear Cell Renal Cell Carcinoma
  • 89Zr-DFO-girentuximab
  • Los Angeles, California
    UCLA
Oct 12, 2023

Head Neck Cancer Trial in Netherlands (PD-L1 imaging, Durvalumab)

Completed
  • Head and Neck Cancer
  • Amsterdam, Netherlands
  • +3 more
Jan 6, 2022

Solid Tumor, Adult Trial in Wuxi (89Zr-NY005)

Not yet recruiting
  • Solid Tumor, Adult
  • Wuxi, Jiangsu, China
    Wuxi No. 4 People's Hospital
Jul 23, 2021

Cervical Cancer, Colorectal Cancer, Esophageal Cancer Trial (89Zr-DFO-girentuximab)

Not yet recruiting
  • Cervical Cancer
  • +13 more
  • (no location specified)
Sep 28, 2022